Present and future of metastatic colorectal cancer treatment: A review of new candidate targets-Reference-Cited by-同舟云学术

Present and future of metastatic colorectal cancer treatment: A review of new candidate targets

Published:2017 Issue:26 Volume:23 Page:4675
ISSN:1007-9327
Container-title:World Journal of Gastroenterology
language:en
Short-container-title:WJG

Author:

Martini Giulia,Troiani Teresa,Cardone Claudia,Vitiello Pietropaolo,Sforza Vincenzo,Ciardiello Davide,Napolitano Stefania,Della Corte Carminia Maria,Morgillo Floriana,Raucci Antonio,Cuomo Antonio,Selvaggi Francesco,Ciardiello Fortunato,Martinelli Erika

Publisher

Baishideng Publishing Group Inc.

Subject

Gastroenterology,General Medicine

Reference100 articles.

1. Global cancer statistics, 2012

2. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

3. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. ERBB receptors and cancer: the complexity of targeted inhibitors

5. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial;International Journal of Colorectal Disease;2024-06-11

2. Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging;Cancers;2024-03-30

3. Classification of molecular subtypes for colorectal cancer and development of a prognostic model based on necroptosis-related genes;Heliyon;2024-03

4. Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial;2024-02-22

5. Long non-coding RNA (lncRNA) PVT1 in drug resistance of cancers; focus on pathological mechanisms;Pathology - Research and Practice;2024-01